Spruce Biosciences posts Q3 2025 results update

Spruce Biosciences, Inc. filed a current report stating that it has released its financial results for the third quarter ended September 30, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Spruce Biosciences, Inc. filed a current report stating that it has released its financial results for the third quarter ended September 30, 2025. The company announced these results, along with corporate updates, in a press release dated November 10, 2025.

The press release is included as Exhibit 99.1 and is furnished, rather than filed, which means it is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Spruce Biosciences (SPRB) disclose in this 8-K filing?

Spruce Biosciences disclosed that it issued a press release announcing financial results for the third quarter ended September 30, 2025, along with corporate updates, and furnished this release as Exhibit 99.1.

Which period do the latest Spruce Biosciences (SPRB) results cover?

The results cover the third quarter ended September 30, 2025. Spruce Biosciences announced these quarterly financial results and related corporate updates in a press release furnished as Exhibit 99.1 to the current report.

How did Spruce Biosciences (SPRB) provide its Q3 2025 financial results?

Spruce Biosciences provided its Q3 2025 financial results through a press release dated November 10, 2025. That press release is furnished as Exhibit 99.1 and incorporated by reference in the current report.

Is the Spruce Biosciences (SPRB) Q3 2025 press release considered filed with the SEC?

No. The company states that the information in Item 2.02 and Item 9.01, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act or automatically incorporated into other filings.

What exhibits are included with this Spruce Biosciences (SPRB) 8-K?

The current report includes Exhibit 99.1, which is the press release dated November 10, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/10/2025 - 04:07 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): November 10, 2025

    

Spruce Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39594	81-2154263
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

611 Gateway Boulevard, Suite 740
South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 415-655-4168

    

     Not Applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SPRB	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit Number		Description

99.1		Press Release of Spruce Biosciences, Inc., dated November 10, 2025

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			SPRUCE BIOSCIENCES, INC.

Date:	November 10, 2025	By:	/s/ Samir Gharib
			Samir Gharib President and Chief Financial Officer

Source: View Original Filing on SEC EDGAR